


2020 Targeted Therapies of Lung Cancer Meeting

PROGRAM



**20 YEARS
OF TARGETED
THERAPIES**

Evolving Targets Innovative Therapies

#TTLC20

FEBRUARY 19-22, 2020 | SANTA MONICA, CALIFORNIA

THANK YOU TO OUR TOP SPONSORS!

DIAMOND

Genentech

A Member of the Roche Group

PLATINUM

AMGEN[®]

Oncology

AstraZeneca 



Bristol-Myers Squibb



2020 Targeted Therapies
of Lung Cancer Meeting

FEBRUARY 19-22, 2020 | SANTA MONICA, CALIFORNIA



20 YEARS
OF TARGETED
THERAPIES

Evolving Targets  Innovative Therapies

CONNECT WITH US

 @IASLC

 facebook.com/IASLC

 linkedin.com

 IASLC

TABLE OF CONTENTS

WELCOME	4
Letter from the President & CEO	4
Letter from Conference Chairs	5
GENERAL CONFERENCE INFORMATION	6
Invited Speakers, Abstract and Poster Presenter Information	8
Venue Floor Plans	10
POSTERS	11
EDUCATIONAL AWARDS	13
SPONSORS & EXHIBITORS	13
Exhibitors & Floor Plan	14
Exhibitor Descriptions	16
SCIENTIFIC PROGRAM	18

W
N
O
C
T
U
R
N

Dear Colleagues and Friends,

Given the rapid pace of change in the lung cancer field, investigators and clinicians face continual pressure to remain abreast of the latest advances in treatment and therapy. The IASLC Targeted Therapies of Lung Cancer Meeting (TTLC) has long sought to assist with that ongoing challenge, providing a forum for the lung cancer community to learn about the newest treatments and how they can be most effectively incorporated into clinical practice.

This year, TTLC is proud to celebrate its 20th anniversary, and on behalf of the IASLC leadership, Board of Directors and conference organizers, we want to thank you for joining us in Santa Monica for this unique event. Over the next three days, you will get an exclusive look at relevant targets for new therapies; data on pre-clinical and early clinical statistics for each of the drugs directed against these targets; presentations on early predictive biomarkers; debates on controversial topics and much more.

It is our wish that you will leave this meeting inspired and hopeful about the latest advances occurring in the lung cancer field. We hope that you will also feel more confident in your grasp of this complex and ever-evolving treatment landscape, not to mention more capable in your ability to affect real and positive change in the lives of your patients.

While you're here, we encourage you to take the time to engage with your friends and peers, as well as to forge new relationships and collaborations. And if you are active on social media, please share what you are learning with the conference's hashtag: #TTLC20. It is only by coming together as a community that we will be able to continue making substantive progress against this disease that affects so many around the world.

Once again, we're so pleased that you have decided to join us for this important event. Welcome to Santa Monica and welcome to the IASLC 2020 Targeted Therapies of Lung Cancer Meeting.



Tetsuya Mitsudomi, MD
President, IASLC

A handwritten signature in black ink, appearing to read "T. Mitsudomi".



Dave Mesko, MBA
Chief Executive Officer

A handwritten signature in black ink, appearing to read "Dave".



Paul A Bunn Jr., MD



Roy Herbst, MD, PhD



Leora Horn, MD



Suresh Ramalingam, MD

Dear Colleagues and Friends,

On behalf of the International Association for the Study of Lung Cancer (IASLC) we are pleased to welcome you to the IASLC 2020 Targeted Therapies of Lung Cancer Meeting (TTLC 2020) at the Fairmont Miramar Hotel & Bungalows. The IASLC Targeted Therapies of Lung Cancer meeting is a dynamic meeting with a long tradition, and over 600 participants will join us this year to share information about ongoing clinical trials of the newest therapies for lung cancer. The meeting presenters summarize the data on relevant targets for new therapies and share data on preclinical and early clinical data for each of the drugs directed against these targets.

We also would like to extend our gratitude and thanks to all sponsors and exhibitors for their continued support to the Targeted Therapies of Lung Cancer Meeting and the IASLC. Without them this conference would not be possible.

Thank you for joining us in Santa Monica.

We look forward to hosting all of you over the next couple of days.

Best Regards,

TTLC 2020 Conference Chairs

Paul A. Bunn, Jr., MD

Roy S. Herbst, MD, PhD

Suresh S. Ramalingam, MD

Leora Horn, MD



GENERAL CONFERENCE INFORMATION

CONFERENCE VENUE

Fairmont Miramar Hotel & Bungalows, 101 Wilshire Blvd, Santa Monica, CA 90401, United States

REGISTRATION AND IASLC INFORMATION DESK, HOTEL LEVEL

Wednesday, February 19 (Hotel Lobby)	14:00 – 19:00
Thursday, February 20 (Wedgewood Foyer)	06:30 – 19:00
Friday, February 21 (Wedgewood Foyer)	06:30 – 18:40
Saturday, February 22 (Wedgewood Foyer)	06:00 – 12:15

EXHIBITION

Exhibition Hall, Hotel Level, Starlight Foyer

February 19	17:00 – 18:00, Welcome Reception
February 20	09:30 – 19:00
February 21	09:30 – 17:00
February 22	08:30 – 12:15

IASLC VIRTUAL LIBRARY

All approved presentation slides and abstracts will be made available as a Virtual Meeting in the IASLC Virtual Library. The TTLC 2020 Virtual Meeting is included in your registration and can be accessed through library.IASLC.org.

Your personal Virtual Meeting Access Code is the same as your Delegate ID Number and can be found on your badge or through your TTLC 2020 registration confirmation email. After you enter your Access Code and confirm your account details, you'll be able to view the presentations that have been marked approved for viewing and marked as "Now Available." To access the Virtual Library, please visit library.IASLC.org.

Given the sensitive nature of some of the presentations at this meeting, certain presentations/slides may have confidentiality restrictions and will not be shared in the Virtual Library

ABSTRACTS

Accepted abstracts will be presented in oral sessions, the poster reception and during networking breaks.

ACCREDITATION

The IASLC TTLC 2020 Meeting is not accredited and does not provide CME credits or certifications for attending sessions.

ATTIRE

Business casual is appropriate for all sessions. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

BADGES AND ACCESS CONTROL

Attendees are requested to wear their name badges at all times in order to participate in the Scientific Sessions and Exhibition. A \$50 USD fee applies for any name badge reprints due to lost name badges.

BREAKFAST

A light breakfast will be provided in the Wedgewood Ballroom from 06:30 – 07:30 on Thursday and Friday, and 06:00 – 07:00 on Saturday.

CELL PHONES

As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

IASLC SOCIAL MEDIA ACCOUNTS TO FOLLOW

Twitter: [**@IASLC**](#)

Facebook: [**FACEBOOK.COM/IASLC**](#)

Youtube: [**IASLC**](#)

Conference Hashtag: [**#TTLC20**](#)

SOCIAL MEDIA POLICY

Given the sensitive nature of some of the presentations at this meeting, we would like to remind attendees that specific presentations may not be shared on any media. Presentations and/or slides that may NOT be shared will be noted at the beginning of each presentation and/or on each slide stating that the material may not be shared. Attendees will be reminded of this policy at the beginning of each session.

VIDEO INTERVIEWS

Video interviews will be conducted in the Wilshire III Ballroom on the lower level.

WIRELESS INTERNET

Wireless internet will be provided in the meeting and exhibit space.

Network: Fairmont

Password: TTLC20

Disclaimer: The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.

INFORMATION FOR INVITED SPEAKERS, ABSTRACT AND POSTER PRESENTERS

Disclosure Information

All speakers must include a slide with their financial disclosure information. Without a disclosure slide you will not be allowed to present.

Presentation Slide Template

All speakers are encouraged to use the IASLC/TTLC presentation slide template for their presentation.

Slide Submission

The IASLC requested that you submit your PowerPoint slides prior to the meeting. If you did not submit your PowerPoint slides prior to or have revised slides, please provide your presentation slides to the technicians in the Starlight Ballroom at least 2 hours prior to your presentation. The use of personal laptops for presentations is not allowed as it can cause technical delays and cut into a presenter's time.

At the time of submission, you will be asked to provide permission to the IASLC to a royalty-free, worldwide, perpetual, irrevocable, nonexclusive and sublicensable license to use, reproduce, publish, translate, distribute, sell and display the presentation. The IASLC realizes that certain slides might include confidential data and will allow those slides to be removed from any broadcast or distribution of the presentation slides. However, you must indicate at the time of submission whether any individual slide contains such confidential information.

Poster Presentations

All Poster Presentation boards are located in the Wedgewood Ballroom, Hotel Level.

Each poster is identified with a poster number that corresponds with the pre-assigned poster number published in this program book. Please visit the IASLC Information & Poster Desk to confirm poster numbers or ask any questions.

POSTER SETUP TIME

Thursday, February 20, 06:00 – 07:45

POSTER TAKE DOWN TIME

Saturday, February 22, 2020, after 09:30

AUTHOR STANDBY TIME

**Thursday,
February 20**

10:00 – 10:20 (Coffee Break)

15:00 – 15:20 (Coffee Break)

17:55 – 18:55 (Poster Viewing Reception)

**Friday,
February 21**

09:55 – 10:15 (Coffee Break)

16:05 – 16:25 (Coffee Break)


**Saturday,
February 22**

09:15 – 09:30 (Coffee Break)




VENUE FLOOR PLANS

Hotel Level



Lower Level



POSTERS

P01

Atypical EGFR Mutations and Co-mutations in Non-Small Cell Lung Cancer Patients Treated with Osimertinib

Jacqueline Aredo

P02

Resistance to EGFR TKI Therapy via Newly Acquired Oncogenic Drivers: Case Series and Review of the Literature of Treatment Outcomes

Nicholas Giustini

P03

Network-based Transcriptome Analysis to Predict Primary Tyrosine Kinase Inhibitor (TKI) Resistance in EGFR-Mutant Lung Adenocarcinomas (LUAD)

Brian Henick

P04

The Role of Continuing Osimertinib with Platinum Doublet Chemotherapy in Patients with Epidermal Growth Factor Receptor (EGFR) Positive Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib

Tejas Patil

P05

Real World Data on Safety and Efficacy of 160 mg Daily Dose of Osimertinib in Patients with Sensitizing EGFR Mutant NSCLC with Brain or Leptomeningeal Metastasis

Dipesh Uprety

P06

Genomic Correlates of Differential Response to EGFR-Directed Tyrosine Kinase Inhibitors

Natalie Vokes

P07

Clinical Outcomes and Co-Occurring Genetic Alterations in Patients with EGFR Exon 20 Insertion Mutations

Gabriela Bravo Montenegro

P08

Phase I Study of Combination Immunotherapy with Ipilimumab and Nivolumab in Patients with Recurrent Extensive Stage Small Cell Lung Cancer (SCLC)

Matthew Austin

P09

Outcomes to First-Line Pembrolizumab in Patients with Non-Small-Cell Lung Cancer and a Poor Performance Status

Joao Victor Alessi

P10

Immune Checkpoint Blockade Response in Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor L858R Mutations

Amy Cummings

P11

CDKN2A Loss Predicts Immunotherapy Response in Stage III/IV NSCLC

Stanley Gutiontov

P12

Determination of Biological Responders Among Those With Radiological Stable Disease to Immune Checkpoint Inhibitors

Jia Luo

P13

Consolidation with Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

Shetal Patel

P14

Clinical Outcomes of EGFR+ NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI)

Andrew Piper-Vallillo

P15

Longitudinal Analysis of PD-L1 and HLA I in Circulating Tumor Cells from Patients with Metastatic Non-Small Cell Lung Cancer Receiving Checkpoint Inhibitor Therapy

Nan Sethakorn

P16

Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with Brain Metastases Treated with Pembrolizumab-Based Therapy

Lova Sun

P17

Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon

Mitchell von Itzstein

P18

ctDNA as a Diagnostic and Prognostic Marker in Patients with KRAS Mutant Non-Small Cell Lung Cancer

Yonina R. Murciano-Goroff

P19

Dynamic Heterogeneity in [18F]-FDG PET Radiomic Features Before and After Neoadjuvant Nivolumab and Association with Major Pathologic Response in Early Stage Non-Small Cell Lung Cancer

Erica C. Nakajima

P20

Predictive Value of High-Risk Clinicopathologic Features for Adjuvant Chemotherapy in Early-Stage Lung Cancer

Ranjan Pathak

P21

Trial in Progress: Circulating Tumor DNA as a Predictive Biomarker to Individualize Therapy in Patients with Inoperable Stage III Non-Small Cell Lung Cancer

Nikhil Shukla

P22

The increasing Role of ALK Positive in improving Outcomes for ALK-Positive Patients

Colin Barton

P23

Investigating the Role of BCL-2 in ALK-Rearranged Non-Small Cell Lung Cancer Treated with ALK-Directed Targeted Therapy

Nathaniel Myall

P24

JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in primary MET Exon14 Skipping Non-small Cell Lung Cancer

Dan Zhao

P25

Phase II Study of Pevonedistat Monotherapy in Previously Treated Patients with Malignant Mesothelioma Harboring Alterations in NF2

Michael Offin

P26

Role of mTOR Inhibitor Everolimus in the Management of Metastatic Thymic Epithelial Tumors and the Use of a Computational Biological Model to Select Patients for Treatment

Jessica Hellyer

P27

The Tumor Immune Microenvironment (TIME) in EGFR-driven Lung Adenocarcinoma: Implications for Disease Recurrence

Maya Khalil

P28

Functional Profile of Major Tumor Infiltrating Lymphocyte Subsets and PD-L1 Expression in Lung Cancer-Associated Brain Metastases

Benjamin Lu

P29

Monocytes and Macrophages Promote Tyrosine Kinase Inhibitor Resistance and Sustained pERK signaling ALK+ Non-Small Cell Lung Cancer

Erin Schenk

P30

The Lung Microbiome and Metabolome are Altered in Lung Cancer Patients

Frank Weinberg



CONGRATULATIONS to our TTLC 2020 Educational Award Winners:

1. Joao Victor Alessi
2. Jacqueline Aredo
3. Matthew Austin
4. Gabriela Bravo Montenegro
5. Yvonne Chao
6. Amy Cummings
7. Nicholas Giustini
8. Stanley Gutiontov
9. Jessica Hellyer
10. Brian Henick
11. Sushma Jonna
12. Jacob Kaufman
13. Maya Khalil
14. Emily Lebow
15. Benjamin Lu
16. Jia Luo
17. Yonina R Murciano-Goroff
18. Nathaniel Myall
19. Erica Nakajima
20. Michael Offin
21. Shetal Patel
22. Ranjan Pathak
23. Tejas Patil
24. Andrew Piper-Vallillo
25. Biagio Ricciuti
26. Nan Sethakorn
27. Nikhil Shukla
28. Lova Sun
29. Dipesh Uprety
30. Natalie Vokes
31. Mitchell von Itzstein
32. Frank Weinberg
33. Dan Zhao

SPONSORS & EXHIBITORS

DIAMOND

Genentech

A Member of the Roche Group

PLATINUM

AstraZeneca



Bristol-Myers Squibb

AMGEN

Oncology

GOLD

Takeda



MERCK

MIRATI
THERAPEUTICS

SILVER

NOVARTIS

Turning Point
Therapeutics

Janssen Oncology

Lilly ONCOLOGY

LOXO
ONCOLOGY

Pfizer Oncology

EMD
SERONO

BRONZE

Boehringer
Ingelheim



gsk

Xcovery
ONCOLOGY

OPENING RECEPTION

Pharma
Mar



Jazz Pharmaceuticals

COFFEE BREAKS

AstraZeneca


AMGEN
Oncology



Bristol-Myers Squibb

Exhibitors & Floor Plans

Booth #	EXHIBITOR	Booth #	EXHIBITOR
1	Amgen	3	IASLC
5	AstraZeneca	7	Merck
2	Bayer	13	Novocure
4	BMS	10	Oncology Learning Network
14	Boehringer Ingelheim	9	Pfizer
15	Genentech	6	Takeda



Exhibitor Descriptions



Oncology

Booth #1

Amgen Oncology is searching for answers to incredibly complex questions that will advance care and improve lives for cancer patients and their families. Our research drives us to understand the disease in the context of the patient's life – not just their cancer journey – so they can take control of their lives.

For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.

At Amgen, we are driven by our commitment to transform the lives of cancer patients and keep them at the center of everything we do.



Booth #5

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.



Booth #2

Bayer is a global Life Sciences leader in cardiopulmonology, hematology, neurology, oncology and women's health. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing innovative therapies and delivering first-in-class educational and support programs to meet their needs. For more information, visit www.bayer.us.



Booth #14

At Boehringer Ingelheim we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.



Booth #4

Bristol-Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients' lives through science.

Genentech

A Member of the Roche Group

Booth #15

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER

Booth #3

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the *Journal of Thoracic Oncology*, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.IASLC.org for more information.



MERCK

Booth #7

For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases.

Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

novocure™

Booth #13

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.



Oncology Learning Network

Booth #10

Oncology Learning Network® is an online resource for the latest developments in oncology practice, providing a customized experience for readers to stay informed about the topics that matter most to them. Through clinical insights, peer-reviewed journal articles, interactive features, research news updates, accredited continuing education (CE) programs, and professional live meetings and events, Oncology Learning Network serves as a collaborative learning and networking environment for a multidisciplinary community of oncology medical professionals. See what's on it for you: www.ONCNET.com.



Booth #9

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma.




Booth #6

The Takeda Oncology mission remains constant—we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Delivering on the unique needs of each person with cancer has been at the core of our oncology business since our inception, and it remains at the very heart of our commitment, research and outreach. The strength and bravery of these individuals inspire and compel us every day.

Alongside our boundary-pushing global R&D unit, Takeda Oncology's proven commercialization capabilities allow us to quickly respond to the diverse and ever-changing needs of patients, healthcare providers and health systems around the world. We are a force of more than 2,000 dedicated oncology professionals, driven by a patient-focused entrepreneurial spirit and commitment to agility.

We are working every day to achieve our aspiration to cure cancer.



FAIRMONT MIRAMAR HOTEL | SANTA MONICA, CALIFORNIA

Co-chairs: Paul A. Bunn, Jr., MD | Roy S. Herbst, MD, PhD | Suresh S. Ramalingam, MD | Leora Horn, MD

SESSIONS: STARLIGHT BALLROOM | **MEALS:** WEDGEWOOD BALLROOM

WEDNESDAY, FEBRUARY 19, 2020

Start	End	Event	Presenter
14:00	19:00	REGISTRATION	
17:00	18:00	WELCOME RECEPTION	
18:00	19:00	DINNER	
19:00	19:05	CEO Welcome	Dave Mesko
19:05	19:10	President's Welcome	Tetsuya Mitsudomi
19:10	19:30	Scientific Talk 1: Lung Cancer Mortality Reduction 2020 Report	Helmneh Sineshaw
19:30	19:50	Scientific Talk 2: Advances in Thoracic Cancer – Past, Present, and Future: An FDA Perspective	Harpreet Singh
19:50	20:05	20 Years of Targeted Therapies: Evolving Targets and Innovative Therapies	Paul A. Bunn Jr., Roy Herbst, Leora Horn, Suresh Ramalingam

THURSDAY, FEBRUARY 20, 2020

Start	End	Event	Presenter
06:30	07:30	BREAKFAST	
7:30	9:45	Session 1 - EGFR TKIs Chairs: Joan Schiller, Thomas Lynch	
7:30	7:40	Science	Pasi Janne
7:40	7:45	Zn-e4	Karen Reckamp
7:45	7:50	HS10296	Lyudmila Bazhenova
7:50	7:55	Reziveritinib (BPI-7711)	Sai-Hong Ou
7:55	8:00	Lazertinib	Keunchil Park
8:00	8:05	Tak788	Howard West
8:05	8:10	Poziotinib	Jacquelyne Robichaux

THURSDAY, FEBRUARY 20, 2020

Start	End	Event	Presenter
8:10	8:15	Osimertinib	Lecia Sequist
8:15	8:20	Tarloxitinib	Viola Zhu
8:20	8:25	Pyrotinib	George Simon
8:25	8:30	CLN-081 (TAS6417)	Helena Yu
8:30	8:35	DZD9008	Deborah Doroshow
8:35	8:40	EGFR + MET (Savolitinib, Tepotinib, Capmatanib)	Mark Kris
8:40	8:45	JNJ61186372	Rachel Sanborn
8:45	8:50	Olecumab (anti-CD73)	Sarah Goldberg
8:50	8:55	Atezo/bev/CT and other 2vs3 or 4	Mark Socinski
8:55	9:00	Afatinib + Necitumumab	Sukhmani Padda
9:00	9:05	Dasatinib	Hatim Husain
9:05	9:10	Navitoclax	Elaine Shum
9:10	9:15	Sepanisertib	Penelope Bradbury
9:15	9:20	Alisertib	Trever Bivona
9:20	9:25	CB 839 Telaglenastat	Greg Otterson
9:25	9:30	Platinum doublet	Ronald Natale
9:30	9:35	Temozolomide + TKI for recurrent brain metastases	Jose Pacheco
9:35	9:45	DISCUSSION	
9:45	10:00	Debate 1 - What Do You Give to Patients With EGFR Mutation in the First Line?" Moderators: Keunchil Park, Jianjun Zhang	
9:45	9:50	TKI + VEGF	Howard West
9:50	9:55	TKI alone	Mark Kris
09:55	10:00	Chemo plus TKI	Philip Bonomi
10:00	10:20	COFFEE BREAK, EXHIBITS & POSTERS	
10:20	12:30	Session 2 - Small Cell Lung Cancer Chairs: Wolf Lindwasser, John Minna	
10:20	10:30	Science	Charles Rudin
10:30	10:35	Nivolumab Combinations	Ticiana Leal
10:35	10:40	Durvalumab +/- Chemo	Jonathan Goldman

THURSDAY, FEBRUARY 20, 2020

Start	End	Event	Presenter
10:40	10:45	Atezolizumab +/- Chemo	Stephen Liu
10:45	10:50	Pembrolizumab +/- Chemo	Victoria Lai
10:50	10:55	Nivolumab + temozolomide	Dwight Owen
10:55	11:00	Dinutuximab	Martin Edelman
11:00	11:05	Lurbinectedin	William Petty
11:05	11:10	PARP Inhibitors	Ben Drapkin
11:10	11:15	Olaparib + temozolomide	Anna Farago
11:15	11:20	AMG 757 (DLL3) + AMG 119 (DLL3) (CAR-T)	Hossein Borghaei
11:20	11:25	GD-2 CAR	Jared Weiss
11:25	11:30	Irinotecan (onidyve)	Paul A. Bunn Jr.
11:30	11:35	PAX5 (BSAP)	Ravi Salgia
11:35	11:40	INCB05987 +/- IO (next to IO at top)	Young Kwang Chae
11:40	11:45	Somatostatin Receptor	Jonathan Lehman
11:45	11:50	AZD2811 + other Aurora Kinase Inhibitors	Carl Gay
11:50	11:55	RRx-001	Daniel Morgensztern
11:55	12:00	Chemo-RT	Roy Decker
12:00	12:05	Chemo + IO + RT	Helen Ross
12:05	12:10	Role of PCI in era of chemo IO	Kristin Higgins
12:10	12:15	Cell free DNA	Wade Iams
12:15	12:20	TAXOL + APG-1252 (Bcl-xL)	Gregory Kalemkerian
12:20	12:30	DISCUSSION	
12:30	13:30	LUNCH	
13:30	15:00	Session 3 - Immune Checkpoint Inhibitors Chairs: David Stewart, Ralph Zinner	
13:30	13:40	Science	Roy Herbst
13:40	13:45	Long term follow up single agent	Neal Ready
13:45	13:50	Long term follow up chemo-combo	David Ettinger
13:50	13:55	Sensitivity and resistance STK11	Ferdinand Skoulidis
13:55	14:00	Sensitivity and resistance HLA microglobulin	Katerina Politi
14:00	14:05	Optimal duration of therapy	David Spigel

THURSDAY, FEBRUARY 20, 2020

Start	End	Event	Presenter
14:05	14:10	Optimal IO endpoints	Yu Shyr
14:10	14:15	ATL001	Rosalyn Juergens
14:15	14:20	ADXS 503	Jennifer Carlisle
14:20	14:25	GRN 1201	Jyoti Patel
14:25	14:30	M7824	Leora Horn
14:30	14:35	KN046 (PDL1-CTLA4 bispecific)	Vamsidhar Velcheti
14:35	14:40	PBF 1129	Dwight Owen
14:40	14:45	CXCL21 Dendritic Vaccine	Aaron Lisberg
14:45	14:50	Neo-PV-01	Kathryn Arbour
14:50	15:00	DISCUSSION	
15:00	15:20	COFFEE BREAK, EXHIBITS & POSTERS	
15:20	15:45	Debate 2 - Optimal therapy for stage 4 NSCLC patient with low PD-L1 expression (1-49%) Moderators: Raymond Osarogiagbon, Chandra Belani	
15:20	15:25	Chemo + PD-1 inhibition	Karen Reckamp
15:25	15:30	Ipi plus Nivo	Matthew Hellman
15:30	15:35	PD-1 Inhibition	Lawrence Einhorn
15:35	16:30	Session 4 - Biomarker Panel Chairs: Dara Aisner, Eva Szabo	
15:35	15:40	IHC/Neoadjuvant	Ignacio Wistuba
15:40	15:45	Multiplex	Kurt Schalper
15:45	15:50	Next Generation Diagnostics for Lung Cancer; Beyond IHC and NGS	David Rimm
15:50	15:55	Tissue and the Issue (blueprint)	Fred Hirsch
15:55	16:00	ctDNA	Max Diehn
16:00	16:05	TMB Tissue	Hossein Borghaei
16:05	16:10	TMB Blood	David R. Gandara
16:10	16:15	RT + IO	Andrea Bezjak
16:15	16:20	WIN Consortium	Amir Onn
16:20	16:30	DISCUSSION	

THURSDAY, FEBRUARY 20, 2020

Start	End	Event	Presenter
16:20	17:55	Session 5 - KRAS/BRAF Chairs: Kristen Marrone, Scott Lippman	
16:30	16:40	Science	Gregory Riely
16:40	16:45	AMG 510	Ramaswamy Govindan
16:45	16:50	MRTX849 (KRAS 9G12C)	Pasi Janne
16:50	17:00	Binimetinib (MEK1/2), MEK162 (Binimetinib + Erlotinib)	Natasha Leighl
17:00	17:05	ROS126766 (BRAF, MEK1/2)	Jose Pacheco
17:05	17:10	LXH254+/-LTT (Pan-RAF)	Ibiayi Dagogo-Jack
17:10	17:15	TAK 580 (Non-V600E) (Pan-RAF)	Glenwood Goss
17:15	17:20	Regorafenib + MTX (Multi-TKI)	Sukhmani Padda
17:20	17:25	SHP2 Inhibitor RMC-4630	Caroline McCoach
17:25	17:30	LY3214966	Alex Adjei
17:30	17:35	Palbociclib + PDO325901 (CDK 4,6 + MEK)	Karen Kelly
17:35	17:40	BVD-523 (ERK1/2)	Bob Li
17:40	17:45	ASN 007	Michael Cheng
17:45	17:55	DISCUSSION	
17:55	18:55	POSTER RECEPTION - WEDGEWOOD BALLROOM	
18:55	20:05	Fellows & Early Career Investigator Session Chairs: Everett Vokes, Leora Horn, Natalie Vokes, Erica Nakajima	
Presidential Remarks			Tetsuya Mitsudomi
Early Faculty			Christine Bestvina
Academic Faculty			Natasha Leighl
Academic Physician Scientist			Chad Pecot
Community/Hybrid			David Spigel
Industry			Cathy Pietanza
Government			Shakun Malik
Leadership			Tetsuya Mitsudomi
Alternative Academics Beyond Clinical Trials			Howard West
Patient Advocacy			Janet Freeman-Daily

FRIDAY, FEBRUARY 21, 2020

Start	End	Event	Presenter
06:30	07:30	BREAKFAST	
7:30	8:30	Session 6 - Surgically Resectable NSCLC Chair: Nasser Altorki, David Harpole	
7:30	7:35	Neoadjuvant IO (Nivo, Atezo, Sintilimab)	David Carbone
7:35	7:40	Neoadjuvant nivo + ipi	Tina Cascone
7:40	7:45	Neoadjuvant IO + Chemotherapy	Catherine Shu
7:45	7:50	Adjuvant IO + Chemotherapy	Nasser Hanna
7:50	7:55	Adjuvant Checkpoint Inhibitors	Heather Wakelee
7:55	8:00	Canakinumab	Jay Lee
8:00	8:05	Crizotinib	David Gerber
8:05	8:10	Osimertinib	Colin Blakely
8:10	8:15	LCMC4	Jamie Chافت
8:15	8:20	IO + PCV in ctDNA Positive Adjuvant Post Resection	Ross Camidge
8:20	8:30	DISCUSSION	
8:30	8:50	Debate 3 - Should IO Be Given Before or After Surgery for Resectable NSCLC? Moderators: Shuangge Ma, Peter Koo	
8:30	8:40	Before	Valerie Rusch
8:40	8:50	After	Jessica Donington
8:50	9:55	Session 7 - Stage 3 NSCLC/Combined Modality Therapy Chairs: Henry S. Park, Christian Rolfó	
8:50	8:55	PACIFIC Trials	Everett Vokes
8:55	9:00	Chemo-RT plus Pembrolizumab	Greg Durm
9:00	9:05	ECOG-ACRIN 5181 (Chemo-RT plus Durva)	Nathan Pennell
9:05	9:10	RT + Atezolizumab	Christine Bestvina
9:10	9:15	RT plus Durva for high PD-L1 Exp NSCLC NRG LU004	Steven Lin
9:15	9:20	Chemo RT plus PARP inhibition	Primo Lara
9:20	9:25	Chemo RT + Metformin	Theodoros Tsakiridis
9:25	9:30	Chemo RT followed by Targeted Therapy: LAURA Study	Suresh Ramalingam
9:30	9:35	RTOG 1308: Proton Vs. Photon	Jeffrey Bradley

FRIDAY, FEBRUARY 21, 2020

Start	End	Event	Presenter
9:35	9:40	RT for oligometastatic NSCLC (NRG LU002)	Kristin Higgins
9:40	9:45	SBRT + Immunotherapy	Roy Decker
9:45	9:55	DISCUSSION	
09:55	10:15	COFFEE BREAK, EXHIBITS & POSTERS	
10:15	10:35	Debate 4 - Should RT be given for a patient responding to IO for oligometastatic NSCLC? Moderators: Navid Hafez, David Berz	
10:15	10:25	Yes	Puneeth Iyengar
10:25	10:35	No	Walter Curran Jr.
10:35	11:45	Session 8 - Antibody Drug Conjugates Chairs: Anne Chiang, Vincent Lam	
10:35	10:45	Science	Pasi Janne
10:45	10:50	DS-1062 (Trop-2)	Jacob Sands
10:50	10:55	DS1205 (AXL)	Helena Yu
10:55	11:00	IMMUNO132 (Trop-2)	Ross Camidge
11:00	11:05	Enapotamab Vedotin	Hossein Borghaei
11:05	11:10	ABBV399 (MET)	Jyoti Patel
11:10	11:15	DS8201 (HER2)	Jose Pacheco
11:15	11:20	ADCT502 (HER2)	Grace Dy
11:20	11:25	BGB324 (AXL TKI)	David Gerber
11:25	11:30	U3-1402 (HER3-directed ADC)	Conor Steuer
11:30	11:35	XMT1536 (NaPi2b)	Melissa Johnson
11:35	11:45	DISCUSSION	
11:45	12:40	Session 9 - FGFR/PDFGR/Angiogenesis/VEGF Chairs: Emily Lin, Mary Jo Fidler	
11:45	11:55	Science	John Heymach
11:55	12:00	Nivolumab + vorolanib	Heather Wakelee
12:00	12:05	Nivolumab + sitravantinib	Kai He
12:05	12:10	EGFR + Bevacizumab or Ramacurumab	Balazs Halmos
12:10	12:15	Ramacurumab + IO	Rathi Pillai

FRIDAY, FEBRUARY 21, 2020

Start	End	Event	Presenter
12:15	12:20	Cabozantinib	Heather Wakelee
12:20	12:25	Nintedanib + IO	Erin Schenk
12:25	12:30	Nintedanib for mutations and its receptors	Ticiana Leal
12:30	12:40	DISCUSSION	
12:40	13:40	LUNCH	
13:40	14:40	Best Abstracts - Oral Presentations Chairs: Erin Gillaspie, Brendon Stiles	
13:40	13:48	OA1: Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Check-point Inhibition in Non-Small Cell Lung Cancer	Biagio Ricciuti
13:48	13:56	OA2: Interferon Gamma Resistance in Setting of LKB1 Loss: Phenotypic Characterization and Investigation of Mechanism	Jacob Kaufman
13:56	14:04	OA3: Detection of NRG1 Gene Fusions in NSCLC	Sushma Jonna
14:04	14:12	OA4: Targeting Inflammatory Monocytes with Dual CCR2/5 Inhibition in Combination with Immune Check-point Inhibition in Lung Squamous Carcinoma	Yvonne Chao
14:12	14:20	OA5: MSK-ACCESS for Non-Invasive Somatic Mutation Profiling of Lung Cancers Utilizing Circulating Tumor DNA: A Prospective Clinical Study	Emily Lebow
14:20	14:40	DISCUSSION & Q&A	
14:40	16:05	Session 10 - ROS1, TRK, ALK, NRG Fusions Chairs: Edward Kaftan, Mary Redman	
14:40	14:50	Science	Alexander Drilon
14:50	14:55	Entrectinib	Robert Doebele
14:55	15:00	Repotrectinib	Sai-Hong Ou
15:00	15:05	Crizotinib	Jessica Lin
15:05	15:10	Lorlatinib	Christine Lovly
15:10	15:15	DS6051b	Elaine Shum
15:15	15:20	Ceritinib +/- Trametinib	Caroline McCoach
15:20	15:25	Larotrectinib	Anna Farago
15:25	15:30	Selitrectinib	Alexander Drilon
15:30	15:35	Ensartinib	Leora Horn
15:35	15:40	Brigatinib	Thomas Stinchcombe

FRIDAY, FEBRUARY 21, 2020

Start	End	Event	Presenter
15:40	15:45	Alectinib + bev or other	Justin Gainor
15:45	15:50	IO post TKI	Corey Langer
15:50	15:55	NRG1 Fusion Inhibitors	Stephen Liu
15:55	16:05	DISCUSSION	
16:05	16:25	COFFEE BREAK, EXHIBITS & POSTERS	
16:25	17:50	Session 11 - RET/MET Inhibitors Chairs: Travis Osterman, Rajwanth Veluswamy	
16:25	16:35	Science	Robert Doebele
16:35	16:40	BLU667 Pralsetinib (RET)	Justin Gainor
16:40	16:45	Loxo292 selpercatinib (RET)	Alexander Drilon
16:45	16:50	TPX-0046 (RET)	Misako Nagasaka
16:50	16:55	RXDX105	Antoinette Wozniak
16:55	17:00	Crizotinib (MET)	Mark Kris
17:00	17:05	Savolitinib (MET)	Mark Awad
17:05	17:10	Topotinib (MET)	Xiuning Le
17:10	17:15	Capmatinib (MET)	Rebecca Heist
17:15	17:20	TPX0022 (MET/CSFR1/SRC)	Sandip Patel
17:20	17:25	APL-101	Aaron Mansfield
17:25	17:30	Merestinib	Julia Rotow
17:30	17:35	REGN 5093	Thomas Marron
17:35	17:40	Sym015 (MET)	Ross Camidge
17:40	17:50	DISCUSSION	
17:50	18:35	Session 12 - Mesothelioma Chairs: Giorgio Scagliotti, Antoinette Wozniak	
17:50	18:00	Science	Harvey Pass
18:00	18:05	Brentuximab	Anne Tsao
18:05	18:10	Anetumab Ravtansine + Pembrolizumab	Kaushal Parikh
18:10	18:15	WT1 Peptide Vaccine and CAR	Matthew Gubens
18:15	18:20	Chemo + IO	Patrick Forde

FRIDAY, FEBRUARY 21, 2020

Start	End	Event	Presenter
18:20	18:25	Neoadjuvant chemo-IO	Anne Tsao
18:25	18:35	DISCUSSION	
19:15	21:15	FACULTY DINNER (BY INVITATION ONLY)	

SATURDAY, FEBRUARY 22, 2020


Start	End	Event	Presenter
06:00	07:00	BREAKFAST	
7:00	9:15	Session 13 - Immunotherapy Combinations Chairs: Peter Ujhazy, John Wrangle	
7:00	7:10	Science	Edward Garon
7:10	7:15	CTLA4 combinations	Jarushka Naidoo
7:15	7:20	PD1 and ICOS	Charu Aggarwal
7:20	7:25	IO + LAG3	Ashwin Somasundaram
7:25	7:30	IO + CD137	Adrian Sacher
7:30	7:35	IO + CDX1140 (anti-CD40)	Rachel Sanborn
7:35	7:40	IO + OX40	Narjust Duma
7:40	7:45	LYC44716	Scott Gettinger
7:45	7:50	Pembrolizumab + vorinostat	Ben Creelan
7:50	7:55	IO+ Epcadostat	Liza Villaruz
7:55	8:00	Pembrolizumab and itacitinib (JAK1)	Joshua Bauml
8:00	8:05	Atezolizumab + Cobimetinib	Ryan Gentzler
8:05	8:10	MGA271	Konstantinos Leventakos
8:10	8:15	Phase I Study of TJ004309 (anti-CD73) in Combination with Atezolizumab in Advanced Cancers	Francisco Robert
8:15	8:20	Talazoparib	Melissa Johnson
8:20	8:25	IO + CCR2/5 Inhibitors	Chad Pecot
8:25	8:30	Siglec 15	Roy Herbst
8:30	8:35	CB 839	Aaron Lisberg
8:35	8:40	Pinabulin	Lyudmila Bazhenova

SATURDAY, FEBRUARY 22, 2020

Start	End	Event	Presenter
8:40	8:45	Monalizumab	Joshua Reuss
8:45	8:50	Comparing effect of IO combinations	Jack Lee
8:50	8:55	Afatinib + Pembro	Benjamin Levy
8:55	9:00	IO + GSK3377794	Ronan Kelly
9:00	9:05	PY314 – anti-TREM2 antibody	Erin Schenk
9:05	9:15	DISCUSSION	
9:15	9:30	COFFEE BREAK, EXHIBITS & POSTERS	
9:30	11:25	Session 14 - mTOR/PI3K/CDK/DNA repair/CHK1/Wee1/PARP inhibition Chairs: Robert Keith, Jeffrey Clarke	
9:30	9:35	Rucaparib	Shirish Gadgeel
9:35	9:40	Prexasertib	Stephen Liu
9:40	9:45	TAK228 (Sapanisertib)	Jonathan Riess
9:45	9:50	Taselisib	Corey Langer
9:50	9:55	Gedatolisib	Zofia Piotrowska
9:55	10:00	ABTL 0812	George Blumenschein
10:00	10:05	mTOR inhibition +PD-1 inhibition	Fadlo Khuri
10:05	10:10	PI3K Inhibition + PD-1 Inhibition	Jennifer Carlisle
10:10	10:15	Sapanisertib + CB-839	Jonathan Riess
10:15	10:20	Sirolimus + Auranofin	Helen Ross
10:20	10:25	Trilaciclib	Jeffrey Crawford
10:25	10:30	MK 8628 & GSK 525762	Taofeek Owonikoko
10:30	10:35	Olaparib	Ben Creelan
10:35	10:40	Talazoparib	Taofeek Owonikoko
10:40	10:45	Niraparib	Zofia Piotrowska
10:45	10:50	VX-970	Deborah Doroshov
10:50	10:55	AZD 6738	Daniel Morgensztern
10:55	11:00	BAY 1895344	Timothy Yap
11:00	11:05	Adavosertib (AZD1775)	Dwight Owen

SATURDAY, FEBRUARY 22, 2020

Start	End	Event	Presenter
11:05	11:10	AZD 0156	Patricia LoRusso
11:10	11:15	DNA PK inhibition	George Simon
11:15	11:25	DISCUSSION	
11:25	12:10	Session 15 – Miscellaneous Chairs: Steven Dubinett, Parneet Cheema	
11:25	11:30	Selinexor	David Gerber
11:30	11:35	Pevonedistat	Angel Qin
11:35	11:40	Nanocisplatin NC 6004	Lyudmila Bazhenova
11:40	11:45	LDOS 47	Afshin Dowlati
11:45	11:50	PF06939999	Rachel Sanborn
11:50	11:55	Auranofin JAK1/STAT3	Helen Ross
11:55	12:00	AG-270 (Agiros MAT2A inhibitor)	Frederick Wilson
12:00	12:10	DISCUSSION	
12:10	12:15	WRAP-UP/CONCLUSION	



2020 Targeted Therapies of Lung Cancer Meeting

EXHIBITORS:

Amgen

AstraZeneca

Bayer

Boehringer Ingelheim

Bristol-Myers Squibb

Genentech

IASLC

Merck

Novocure

Oncology Learning Network

Pfizer

Takeda

Located
in the
**STARLIGHT
FOYER**



**20 YEARS
OF TARGETED
THERAPIES**

Evolving Targets  Innovative Therapies

Help us create hope and fund research!

DONATE TODAY

WHY SUPPORT THE ILC FOUNDATION?

The answer is simple. We fund fellowships to support innovative research for conquering lung cancer. Every dollar you give to the ILC Foundation goes straight to research.

IASLC.org/ILC-Foundation



**INTERNATIONAL
LUNG CANCER
FOUNDATION**



I N S P I R I N G H O P E T H R O U G H R E S E A R C H



Visit **keytruda.com/hcp**
to learn more about **KEYTRUDA:**

- Approved indications
- Resources for health care professionals
- The Merck Access Program
- KEY+YOU Support Program for patients





Currently Enrolling



Orchestrating a new investigational approach to researching MET-altered cancers

NCT03175224

Phase 1/2 Study of APL-101 in Subjects with c-Met Dysregulation (Overexpression, Amplification or/and EXON 14 Skip Mutations) in Solid Tumors

Featuring APL-101*

An investigational, Type 1, selective, and specific c-Met inhibitor currently in clinical development, with preclinical potency against HGF dependent and independent models, favorable preclinical efficacy compared to other selective c-Met inhibitors, and demonstrated blood brain barrier penetration

For full eligibility requirements, please visit ClinicalTrials.gov

Interested in enrolling a subject or conducting this trial at your Institution?

Call **1-844-7-SPARTA/1-844-777-2782** (US only) to speak with a representative.

*APL-101 is an investigational agent. Its safety and efficacy have not been established by any agency.

V1 | 21JAN2020 | APL-101-01

Never miss out on another presentation!

Your personal Virtual Meeting Access Code is the same as your Delegate ID Number and can be found on your badge or through your TTLC 2020 registration confirmation email. After you enter your Access Code and confirm your account details, you'll be able to view any presentations that have been marked as "Now Available." To start viewing, please visit library.IASLC.org.



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

**Access the
TTLC 2020
Conference
Sessions**


**Anytime,
Anywhere**

**Get the 2020
Targeted Therapies
of Lung Cancer Virtual
Meeting via**

[LIBRARY.IASLC.ORG](https://library.IASLC.org)



IASLC



HOT TOPIC MEETING: LIQUID BIOPSY

BALTIMORE, MARYLAND | MAY 7-9, 2020

SAVE THE DATE!

Learn about the new advances in liquid biopsy technology and clinical applications, while experiencing professional camaraderie with lung cancer experts.

Registration
Opens
MARCH 1, 2020

#LIQUIDBIOPSY20


MEETING CHAIRS:

Dr. Maria Arcila, MD

Dr. David Gandara, MD

Dr. Christian Rolfo, MD, PhD, MBA

www.IASLC.org/liquidbiopsy



JTO
Impact Factor
increases to
12.460!

Ranked **10th** among **229**
oncology journals

Ranked **3rd** among **63**
respiratory medicine
journals

JTO is the **#1** journal in
thoracic malignancies,
according to Editor-in-Chief,
Alex A. Adjei, MD, PhD




INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

Official Publication of the International Association for the Study of Lung Cancer

Journal of Thoracic Oncology

Volume 14, Number 6, June 2019



IASLC



2020 North America Conference on Lung Cancer

OCTOBER 15-17, 2020 | CHICAGO, ILLINOIS

SAVE THE DATE!

REGISTRATION
OPENS
APRIL 2020

#NACLC20

CONQUERING THORACIC CANCERS WORLDWIDE



2020 World Conference on Lung Cancer

AUGUST 9-12, 2020 | SINGAPORE

**REGISTER
NOW FOR
WCLC 2020**

EXPERIENCE


the latest advances in thoracic oncology at
the world's largest collaborative gathering
of lung and thoracic cancer specialists
from all disciplines.

wclc2020.IASLC.org

CONQUERING THORACIC CANCERS WORLDWIDE

Announcing the launch of

JTO CLINICAL AND RESEARCH REPORTS



A new open access journal from the IASLC

JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the *Journal of Thoracic Oncology* by offering authors a gold open access publication option and publishing the following article types in particular:

- Phase I trials
- Well performed single-arm Phase II trials
- Small to moderate-sized randomized Phase II trials
- Subset analyses of published trials
- Impactful retrospective studies
- Database and registry analysis
- Large institutional series
- High-quality case reports
- Region-specific clinical trials
- Subspecialty specific thoracic oncology studies
- Selected high-quality meeting reports



Learn more at JTOCRR.org

NOW CALLING FOR INTERNATIONAL PARTICIPATION

Contribute Data to the IASLC 9th Edition Lung Cancer Staging Project

Financial support may be available

Help change the landscape of lung cancer treatment for future patients!

- New clinical and molecular elements have been added
- International participation is crucial to the project's success
- The 9th Edition recommendations will be developed in 2022

TIMELINE:

The study consists of lung cancer patients diagnosed between January 1, 2011 and December 31, 2019.

Cases may be submitted through 2021.

For more information:
www.iaslc.org/staging



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

IASLC 2020

Meetings Schedule

FDA-AACR-IASLC Workshop to Address the Criticality of Tobacco Use Assessment in Oncology Therapeutic Trials

February 28, 2020 | Silver Springs, MD
#FDAWorkshop20

European Lung Cancer Congress 2020

April 15-18, 2020 | Geneva, Switzerland
#ELCC20

Lung Cancer Hot Topic: Liquid Biopsy

May 7-9, 2020 | Baltimore, MD
#LiquidBiopsy20

IASLC 2020 World Conference on Lung Cancer

August 9-12, 2020 | Singapore
#WCLC20

IASLC 2020 North America Conference on Lung Cancer

October 15-17, 2020 | Chicago, IL
#NACLC20

Lung Cancer Hot Topic: Immunotherapy

November 2020

CONNECT WITH US

 @IASLC

 facebook.com/IASLC

 linkedin.com

 IASLC



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide



Join more than 8,000 thoracic oncology specialists...

**JOIN THE
IASLC
TODAY!**

Become an IASLC Member

Here are just some of the benefits IASLC members enjoy:

- › Scientific publications offering: member access to *IASLC Lung Cancer News/Journal of Thoracic Oncology*, and discount publication fees for the new open-access *Journal of Thoracic Oncology Clinical and Research Reports*
- › Networking opportunities within the ONLY global, multidisciplinary network dedicated to the study and eradication of thoracic malignancies
- › Discounts to the IASLC World Conference on Lung Cancer and other IASLC-sponsored scientific and educational meetings
- › Committee opportunities
- › Access to the IASLC member directory

To learn more about the different levels of membership and benefits, visit:

www.iaslc.org/join, visit the IASLC Booth or reach out to membership@iaslc.org



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

THANK YOU TO OUR SPONSORS!

DIAMOND

Genentech

A Member of the Roche Group

PLATINUM

AstraZeneca

AMGEN
Oncology



Bristol-Myers Squibb

GOLD



MIRATI
THERAPEUTICS

SILVER



BRONZE



OPENING RECEPTION



2020 Targeted Therapies
of Lung Cancer Meeting

FEBRUARY 19-22, 2020 | SANTA MONICA, CALIFORNIA



20 YEARS
OF TARGETED
THERAPIES

Evolving Targets Innovative Therapies



#TTLC20



**2020 Targeted Therapies
of Lung Cancer Meeting**

FEBRUARY 19-22, 2020 | SANTA MONICA, CALIFORNIA

13100 East Colfax Avenue | Unit 10 | Aurora, CO 80011 USA | www.IASLC.org